There are more therapeutic options in the management of type 2 diabetes, with many people utilising non-insulin therapies, some of which are weight-neutral (metformin and dipeptidyl-peptidase 4 inhibitors) or promote weight loss (glucagon-like peptide 1 agonists or sodium-glucose transport protein 2 inhibitors) compared to agents that promote weight gain (insulin, Sulphonylureas and Pioglitazone). This evidence concerns the gene INS and type 2 diabetes mellitus.